Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement

Rhea-AI Summary

Indaptus Therapeutics (Nasdaq: INDP) has announced a $3.0 million registered direct offering and concurrent private placement. The company will issue and sell 1,643,837 shares of common stock at $1.825 per share, along with unregistered warrants to purchase an equal number of shares. The warrants, exercisable at $1.70 per share, will have a five-year term. Paulson Investment Company, is acting as the exclusive placement agent. The offering is expected to close around August 8, 2024. Indaptus plans to use the net proceeds to fund research and development activities and for working capital and general corporate purposes.

Positive

• Secured $3.0 million in funding through a registered direct offering and private placement
• Warrants issued have a five-year term, providing long-term potential for additional capital
• An officer of Indaptus participated in the offering, showing insider confidence

Negative

• Potential dilution of existing shareholders due to the issuance of new shares and warrants
• The offering price of $1.825 per share may be at a discount to the current market price
• Additional expenses related to the placement agent's fees and other offering costs will reduce the net proceeds

Insights

Financial Analyst

Indaptus Therapeutics' $3.0 million registered direct offering and concurrent private placement is a strategic move to bolster its financial position. The $1.825 per share pricing represents a 13.5% discount to the previous closing price, which is within typical range for such offerings. The inclusion of warrants at $1.70 per share provides potential for additional capital influx if exercised.

While the offering dilutes existing shareholders by approximately 16%, it's a necessary step for a clinical-stage biotech to fund ongoing R&D. The participation of an officer in the offering signals internal confidence. However, investors should note that the $3.0 million raise is relatively small and may only provide a short runway, potentially necessitating further capital raises in the near future.

Biotech Industry Expert

This capital raise is important for Indaptus Therapeutics' ongoing research in cancer and viral infection treatments. The $3.0 million influx, while modest, can significantly extend the company's operational runway. For clinical-stage biotechs, consistent funding is vital to progress through costly clinical trials and regulatory processes.

Investors should focus on Indaptus' pipeline progress and upcoming milestones. The company's ability to attract investment, albeit small, in a challenging market for biotechs is noteworthy. However, the relatively small raise suggests either a targeted approach to immediate needs or potential difficulties in securing larger investments. Future success will hinge on clinical trial outcomes and the company's ability to leverage this capital effectively.

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,643,837 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,643,837 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.825. The warrants will have an exercise price of $1.70 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about August 8, 2024, subject to the satisfaction of customary closing conditions.

Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with the offering.

The gross proceeds to Indaptus from the offering are expected to be approximately $3.0 million, before deducting the placement agent’s fees and other offering expenses payable by Indaptus. Indaptus intends to use the net proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes.

The shares of common stock were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-267236), including a base prospectus, previously filed with the Securities and Exchange Commission (“SEC”) on September 1, 2022 and declared effective by the SEC on September 9, 2022. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained by contacting Donald A. Wojnowski Jr. of Paulson Investment Company, LLC at (646) 553-3691 or at dwojnowski@paulsoninvestment.com.

The warrants issued in the private placement and shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(b) of Regulation D promulgated thereunder, have not been registered under the Securities Act or applicable state securities laws and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding the gross proceeds from the registered direct offering and private placement and anticipated use of the net proceeds. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Indaptus’ actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to risks related to market conditions. Other important factors discussed under the caption “Risk Factors” included in Indaptus’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC on May 8, 2024, its most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and its other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Indaptus undertakes no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: investors@indaptusrx.com

Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com

Media:
Cuttlefish Communications
Shira Derasmo
shira@cuttlefishpr.com
917-280-2497

FAQ

What is the size of Indaptus Therapeutics' (INDP) recent offering?

Indaptus Therapeutics (INDP) announced a $3.0 million registered direct offering and concurrent private placement.

How many shares is Indaptus Therapeutics (INDP) issuing in the offering?

Indaptus Therapeutics (INDP) is issuing 1,643,837 shares of common stock in the offering.

What is the exercise price of the warrants issued by Indaptus Therapeutics (INDP)?

The warrants issued by Indaptus Therapeutics (INDP) have an exercise price of $1.70 per share.

When is the expected closing date for Indaptus Therapeutics' (INDP) offering?

The offering is expected to close on or about August 8, 2024, subject to customary closing conditions.

How does Indaptus Therapeutics (INDP) plan to use the proceeds from the offering?

Indaptus Therapeutics (INDP) intends to use the net proceeds to fund research and development activities and for working capital and general corporate purposes.